The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Esketamine Nasal Spray versus Quetiapine for Resistant Depression
Open accessAbstract
To the Editor: In their article on the ESCAPE-TRD trial, Reif et al. (Oct. 5 issue) 1 report on the efficacy and safety of esketamine nasal spray in comparison with extended-release quetiapine therapy in patients with treatment-resistant depression. The between-group differences in the change from baseline in the score on the Montgomery–Åsberg Depression Rating Scale (MADRS; scores range from 0 to 60, with higher scores indicating more severe depression) at 8 weeks (−2.8 points, favoring esketamine) and 32 weeks (−2.2 points, also favoring esketamine) were significant but were less than the minimum clinically important difference. 2 The data on remission that were . . .
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistics Notes: Blinding in clinical trials and other studies
Day, S. J. (2000) · BMJ · doi:10.1136/bmj.321.7259.504 · Cited by 482
Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression
Reif, A., Bitter, I., Buyze, J., Cebulla, K., Frey, R., Fu, D.-J., Ito, T., Kambarov, Y., Llorca, P.-M., Oliveira-Maia, A. J., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2304145 · Cited by 222
Posternak, M. A., & Zimmerman, M. A. (2007) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.106.028555 · Cited by 155
Potts, M. K., Daniels, M. L., Burnam, M. A., & Wells, K. B. (1990) · Journal of Psychiatric Research · doi:10.1016/0022-3956(90)90005-b · Cited by 147
Duru, G., & Fantino, B. (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x291958 · Cited by 125
Hengartner, M. P., & Plöderl, M. (2022) · BMJ Evidence-Based Medicine · doi:10.1136/bmjebm-2020-111600 · Cited by 114
Self-citationClinical trials and the response rate illusion
Kirsch, I., & Moncrieff, J. (2007) · Contemporary Clinical Trials · doi:10.1016/j.cct.2006.10.012 · Cited by 80
How do psychiatric drugs work?
Moncrieff, J., & Cohen, D. (2009) · BMJ · doi:10.1136/bmj.b1963 · Cited by 79
Towards achieving remission in the treatment of depression
Mendlewicz, J. (2008) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2008.10.4/jmendlewicz · Cited by 59
Critical approach to antidepressant trials
EVEN, C., Siobud-Dorocant, E., & Dardennes, R. M. (2000) · The British Journal of Psychiatry · doi:10.1192/bjp.177.1.47 · Cited by 48
Research works printed but not linked: 1
- 10.1136/bmjebm-2020-111600 · DOI · Paper page
Cited by
Naudet, F., Pellen, C., Fodor, L. A., Gastaldon, C., Barbui, C., Turner, E. H., Le Pabic, E., & Cristea, I. A. (2025) · BMC Medicine · doi:10.1186/s12916-025-04435-x · Cited by 6
“However, the study was criticized [20, 21] for its design and analytical choices, which may have exaggerated the observed differences between the groups, despite the arguably small difference in means ( − 2.2 points [95% CI, − 3.6 to − 0.8]).”
InfluentialSelf-citation
Metadata
- Authors
- Horowitz, M. A., Plöderl, M., & Naudet, F.
- Affiliations
- Royal Marsden NHS Foundation Trust (GB)
- Paracelsus Medical University (AT)
- CIC Rennes (FR)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-01-04
- Volume
- 390
- Issue
- 1
- Pages
- 93-95
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4390547870
- Cited by
- 1
- References
- 13
- Citations by year
- 2025: 1
- Type
- journal article
- Language
- en
- Open access
- green
- hal.science
- Licence
- cc-by-nc-nd
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion, cc-by-nc-nd)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- esketamine, nasal spray, quetiapine, treatment-resistant depression, antidepressant efficacy, remission, minimal clinically important difference, Montgomery-Asberg Depression Rating Scale
- MeSH terms
- Quetiapine Fumarate, Antidepressive Agents, Depression, Humans, Ketamine, Nasal Sprays
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Esketamine Nasal Spray versus Quetiapine for Resistant Depression. https://app.cochat.ai/papers/10.1056/nejmc2313230
- The paper
- Horowitz, M. A., Plöderl, M., & Naudet, F. (2024). Esketamine Nasal Spray versus Quetiapine for Resistant Depression. New England Journal of Medicine. https://doi.org/10.1056/nejmc2313230
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.